Home » Enzon Sells Interest in Schering Drug
Enzon Sells Interest in Schering Drug
Enzon Pharmaceuticals Inc. said Monday it sold a 25 percent share in Schering-Plough’s hepatitis C drug Peg-Intron to privately held Drug Royalty Corp. for $92.5 million.
Hemscott
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May